Geneva, Switzerland, April 17, 2025 - In a significant move within the biopharmaceutical industry, Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage company dedicated to the development of innovative small molecule allosteric modulators for neurological disorders, has announced the termination of its partnership with Janssen Pharmaceuticals, Inc., now rebranded as J&J Innovative Medicine. This announcement comes in the wake of the previously disclosed decision to halt the development of ADX71149 (JNJ-40411813) for epilepsy.

The decision to terminate this collaboration means that Janssen has returned all rights related to the development and commercialization of ADX71149 back to Addex. This transition of rights marks a pivotal moment for Addex, allowing the company to regain full control over a promising asset that has successfully completed three Phase 2 clinical trials. Tim Dyer, CEO of Addex, expressed his enthusiasm regarding this development, stating, ADX71149 is a high quality asset which has completed three Phase 2 studies so we are excited to regain control of its development from our partner with its high quality data package and significant material. He further elaborated on the company's future strategy by indicating that they are currently evaluating various high-value therapeutic indications for ADX71149 and are actively pursuing discussions with potential partners for its future development.

Addex Therapeutics, founded with a vision to pioneer treatments for neurological disorders, has a diverse portfolio of drug candidates. Its lead compound, dipraglurant, which acts as a negative allosteric modulator (NAM) of the mGlu5 receptor, is under investigation for its potential in facilitating recovery from brain injuries, including those resulting from strokes and trauma. Additionally, Addex has partnered with Indivior to advance a GABAB positive allosteric modulator (PAM) drug candidate targeting substance use disorders, while the company is also developing an independent GABAB PAM program aimed at treating chronic cough.

The company holds a 20% equity stake in Neurosterix LLC, a private company that is also pursuing advanced allosteric modulator programs. These programs include innovative treatments for schizophrenia, mood disorders, and mild neurocognitive disorders. Addex Therapeutics is publicly listed on the SIX Swiss Exchange, and its shares are represented in the form of American Depositary Shares traded on the NASDAQ Capital Market under the ticker symbol ADXN. For further information on the companys developments, visit their official website at